Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospective clinical trial exists to guide recommendations for optimal and more specific immunosuppressive treatments rather than corticosteroids, further studies may lead to a more mechanistic-based approach towards these toxicities in the future. In relation to current practice, we recommend adherence to the recent published guidelines which emphasize the importance of early recognition and administration of temporary immunosuppressive therapy with corticosteroids in most cases, depending on the organ system involved, and the severity of toxicity. Recognition of these toxicities is increasingly important as the use of these agents expand within different indications for patients with lung cancers, and to other tumor types.
KeywordsLung cancer Immune checkpoint inhibition Side effect Anti-PD-1 Anti-PD-L1
Compliance with Ethical Standards
Conflict of Interest
Beatriz Wills declares that she has no conflict of interest.
Julie R. Brahmer has received research support through grants from Bristol-Myers Squibb, MedImmune/AstraZeneca, and Merck; has received compensation from Celgene, Merck, and Lilly for service as a consultant; has received compensation from Merck, Genentech, and Syndax for participation on advisory boards; and has served on advisory boards and as a consultant for Bristol-Myers Squibb but received no compensation.
Jarushka Naidoo has received research support through grants from Merck and MedImmune/AstraZeneca and has received compensation from Bristol-Myers Squibb and Takeda for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance.
- 1.GLOBOCAN 2012 v1.0: cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon: International Agency for Research on Cancer, 2013 (http://globocan.iarc.fr.ezp.welch.jhmi.edu).
- 4.• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. Checkmate 017: randomized, open-label, international phase 3 study that showed that overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel patients with advanced, previously treated squamous-cell NSCLC.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.• Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50. KEYNOTE-010: phase 2/3 study that showed that pembrolizumab prolongs overall survival and has a favorable benefit t-to-risk profile in patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.CrossRefPubMedGoogle Scholar
- 8.• Rittmeyer A, Barlesi F, Waterkamp, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. OAK phase 3 study that showed that atezolizumab resulted in clinically significant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology.CrossRefPubMedGoogle Scholar
- 9.• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29. PACIFIC: Phase 3 study that showed that progression-free survival was significantly longer with durvalumab than with placebo in patients with h locally advanced, unresectable, non-small-cell lung cancer (NSCLC).CrossRefPubMedGoogle Scholar
- 10.Hellmann M, Ramalingam S, Reck M, O'Byrne K, Paz-Ares L, Harbison CT, et al. An open label randomized phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC)(CheckMate 227). J Immunother Cancer. 2015;3(2):P154.CrossRefPubMedCentralGoogle Scholar
- 11.• Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104. CheckMate227: phase 3 trial that showed that progression-free survival was significantly longer with combination therapy first with nivolumab than with chemotherapy among patients with NSCLC and high tumor mutational burden, irrespective of PD-L1 expression level.CrossRefPubMedGoogle Scholar
- 12.• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92. KEYNOTE-189: Phase 3 trial that showed that the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone in patients with patients with previously untreated metastatic NSCLC without EGFR or ALK mutations.CrossRefPubMedGoogle Scholar
- 16.Hwang WL, Niemierko A, Hwang KL, et al. Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy. JAMA Oncol. 2017; https://doi.org/10.1001/jamaoncol.2017.3808.
- 17.Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017; https://doi.org/10.1016/j.chest.2017.04.177.
- 19.••Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary. J Oncol Pract. 2018:JOP-18. First systematic review based guideline that offers a multidisciplinary recommendation of the management of immune-related adverse events, are based on.Google Scholar
- 21.Puzanov I, Diab A, Abdallah K, Bingham CO, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2016:annrheumdis-2016.Google Scholar
- 37.Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, Van Thienen JV, van Leerdam ME, van den Heuvel MM, Blank CU, van Dieren J, Haanen JB. Immune checkpoint inhibition-related colitis: correlation between ulcers and need for infliximab.Google Scholar
- 48.Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–81.CrossRefPubMedGoogle Scholar
- 49.Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2016:annrheumdis-2016.Google Scholar